Johnson & Johnson’s nasal spray will reduce depression, approval to reduce suicide risk

Spread the love

A nasal spray from Johnson & Johnson has been approved to reduce cases of suicide. The Food and Drug Administration states that Johnson & Johnson’s Spraveto can be actively selected as an antidepressant.

At present, most of the people of the world coming into depression are choosing the path of suicide very easily. Recently, a nasal spray from Johnson & Johnson has been approved to reduce cases of suicide.

The Food and Drug Administration has approved Johnson & Johnson’s Spraveto. Administration has stated that Johnson & Johnson’s Spraveto can actively make good choices as an antidepressant.

Michel Kramer, vice president of Johnson & Johnson’s Neurosciences Medical-Units Unit, says the Spraveto has been used in the corona era to deprive people. Which has helped them a lot to get rid of depression. Michel Kramer states that 11% to 12% of the 17 million Americans currently suffer from depression.

Kremer said that since its approval in March 2019, Spraveto has been used on about 6,000 people for treatment-resistant depression. This sparvetto of Johnson & Johnson was used on the victims of depression and depression. After which the study conducted found that this drug has been tested positively on people contemplating suicide.

Gerard Sanacora, director of depression research at Yale, said, “The study of the drug suggests that it can provide a new way for physicians to quickly assist patients in the midst of an urgent depressive episode and help them Can do.”

Leave a Reply

Your email address will not be published. Required fields are marked *